Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
NEW YORK, Jan. 15, 2016 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Eastern District of Michigan on behalf of investors who purchased Esperion Therapeutics, Inc. (NASDAQ:ESPR) securities between August 18, 2015 and September 28, 2015.
Click here to learn about the case: http://docs.wongesq.com/ESPR-Info-Request-Form-1062. There is no cost or obligation to you.
The complaint alleges that Defendants issued false and misleading statements regarding the Company’s business and prospects, including that there was no clear path to approval for ETC-1002, the Company’s lead product candidate designed to lower LDL-cholesterol levels, and that the FDA had encouraged the Company to initiate a cardiovascular outcomes trial (“CVOT”) and that completion of a CVOT could be necessary prior to approval of ETC-1002.
On August 17, 2015, Esperion reported to investors material events from an August 2015 meeting with the FDA; the Company stated that during the meeting it was informed by the FDA that the Company would not have to complete a CVOT to gain approval of ETC-1002. Then in a September 28, 2015 news release the Company noted that the FDA had actually “encouraged the Company to initiate a cardiovascular outcomes trial promptly” and it may be necessary to have a completed CVOT prior to approval.
If you suffered a loss in Esperion Therapeutics you have until March 14, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/ESPR-Info-Request-Form-1062.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
